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Modulation of renal disease in MRL/lpr mice by pharmacologic sis factor- (TNF-) and nitric oxide (NO) [4, 5]. NO is
inhibition of inducible nitric oxide synthase. produced in large quantities after exposure of infiltrating
Background. MRL-MPJFaslpr (MRL/lpr) mice spontaneously macrophages and resident mesangial cells to inflamma-develop lupus-like disease characterized by immune complex
tory mediators [6–8]. NO can react with O2 radicals toglomerulonephritis and overproduction of nitric oxide (NO).
form peroxynitrite with subsequent metabolism generat-Blocking NO production pharmacologically by a non-specific
nitric oxide synthase (NOS) inhibitor ameliorated renal disease ing highly reactive and toxic hydroxyl radicals (HO·)
in MRL/lpr mice while genetically deficient inducible NOS [9, 10]. NO also may inhibit cell function by formation
(iNOS) mice developed proliferative glomerulonephritis simi- of iron-nitrosyl complexes in enzymes containing iron-lar to wild-type controls.
groups or may nitrate tyrosine residues, thus altering theMethods. To clarify the role of iNOS in the pathogenesis
function of proteins such as catalase [11, 12].of nephritis in MRL/lpr mice, we treated mice with two differ-
ent NOS inhibitors. Either NG-monomethyl-l-arginine (L-NM- Urine measurements of nitrate and nitrite (N/N, stable
MA), a nonspecific NOS inhibitor, or l-N6-(1-iminoethyl)lysine metabolites of NO) are a marker of endogenous NO
(L-NIL), an iNOS specific inhibitor, was administered in the
production [13]. We have previously demonstrated thatdrinking water from 10 through 22 weeks of age with disease
MRL/lpr mice have elevated levels of N/N in their urineprogression monitored over time. Control mice received water
alone. compared to control strains [14]. This increase in urinary
Results. Both L-NMMA and L-NIL blocked NO production N/N begins at 10 to 12 weeks of age and predates the
effectively in MRL/lpr mice. As expected, neither L-NNMA onset of proteinuria in these mice. Treatment with thenor L-NIL had an effect on antibody production, immune com-
non-specific NOS inhibitor (NG-monomethyl-l-arginine,plex deposition or complement activation. Although both NOS
L-NMMA) blocks NO production [15], decreases pro-inhibitors decreased protein excretion, L-NMMA was more
effective than L-NIL. Pathologic renal disease was significantly teinuria and yields lower pathologic renal scores in both
decreased at 19 weeks in both treatment groups. At 22 weeks NZB/NZW and MRL/lpr mice compared to controls
the L-NIL treated mice, but not the L-NMMA mice, had sig-
[14, 16]. In contrast, MRL/lpr iNOS knockout mice de-nificantly reduced renal disease scores compared to controls.
velop similar renal disease to wild-type MRL/lpr miceConclusion. These results indicate that specific inhibition of
iNOS blocks the development of pathologic renal disease in [17]. To clarify these seemingly disparate results between
MRL/lpr mice. pharmacologic inhibition of all NOS isotypes versus spe-
cific genetic inhibition of only iNOS production, we as-
sessed the effect in MRL/lpr mice of specific pharma-
MRL-MPJFaslpr (MRL/lpr) mice spontaneously develop cologic inhibition of iNOS by using L-NIL, a specific
immune complex glomerulonephritis similar to that seen inhibitor of iNOS, versus non-specific inhibition of all
in human lupus [1, 2]. Interaction of immune complexes NOS isotypes using L-NMMA.
with resident glomerular mesangial cells triggers an in-
flammatory cascade characterized by mononuclear cell
METHODSrecruitment, mesangial cell proliferation and matrix pro-
tein accumulation [3]. Mediators released during renal Mice
inflammation include interferon- (IFN-), tumor necro- Eight-week-old female MRL/lpr mice were purchased
from the Jackson Laboratory (Bar Harbor, ME, USA),
Key words: lupus, rodent, autoantibody, inflammation, nitric oxide. housed under specific pathogen-free conditions at the
Ralph H. Johnson VAMC animal facility and provided 2002 by the International Society of Nephrology
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autoclaved food and sterile water ad libitum. Mice were methylbenzidene (TMB; Sigma) was added in 0.1 mol/L
citrate buffer (pH 4) and 0.015% H2O2. Absorption atrandomly tested and were serologically negative for com-
mon murine pathogens. OD380 was determined on a microtiter plate reader (Dy-
natech, McLean, VA, USA). Results are shown as the
Treatment OD380 at a 1/100 dilution. Double stranded DNA was
derived by S1 nuclease (Sigma) treatment of phenol ex-At 10 weeks of age mice were placed on a defined
N/N-free diet (Zeigler Brothers, Gardners, PA, USA) tracted calf thymus DNA. Anti-glomerular basement
membrane (GBM) antibodies were measured using aand given water containing L-NMMA (50 mmol/L) or
l-N6-(1-iminoethyl)lysine (L-NIL; 1 mg/mL). Controls previously described ELISA-based assay [18].
received distilled water without additives. There was no
Total Igdifference in animal weights, food consumption or water
consumption between the treatment groups. We have Total IgG, IgG2a and IgG3 levels in the sera were
determined by ELISA using a standard curve of knownpreviously determined that the N/N-free diet alone has
no effect on disease expression in MRL/lpr mice (Gilke- concentrations of total mouse IgG or specific isotypes.
ELISA plates were coated with 1 g/mL anti-mouse im-son, unpublished data).
munoglobulin (-chain specific; Southern Biotechnol-
Reagents ogy, Birmingham, AL, USA) and incubated overnight
at 4C. Sera were added in serial dilutions starting atl-N6-(1-iminoethyl)lysine (L-NIL) was a gift from Phar-
macia Corporation, (St. Louis, MO, USA). L-NMMA 1/1000 dilution. HRP-conjugated goat anti-mouse IgG
(-chain specific; Sigma) or specific anti-isotype reagentswas purchased from Cyclops (Pittsburgh, PA, USA). All
other reagents were purchased from Sigma Chemical were added, followed by TMB for color development.
OD380 absorbance was measured as above.Co. (St. Louis, MO, USA).
Nitrate/nitrite analysis Tail cuff measures
At 19 weeks of age, systolic blood pressures wereNitrate/nitrite were measured in urine as previously
described [13]. Briefly, urine samples were filtered using measured by tail cuff. Briefly, mice were placed in restric-
tion chambers on a warmed surface and allowed to accli-Centricon ultrafiltration tubes (Amicon, Beverly, MA,
USA). Nitrate was converted to nitrite using nitrate re- mate to the surroundings. A rubber-sealed cuff was
placed around the animal’s tail and connected to a pres-ductase (Boehringer Mannheim, Indianapolis, IN, USA),
and total N/N was determined by measuring nitrite via sure transducer and recording computer (Visitech Sys-
tems, Apex, NC, USA). Ten separate pressure measure-the Greiss reaction. Known amounts of N/N were used
to generate a standard curve. ments were recorded and averaged for each mouse. A
mercury manometer was used to calibrate the equipment
Urine protein excretion before each set of recordings.
Mice were placed in metabolic cages for 24-hour urine
Pathologycollections. To prevent bacterial growth, antibiotics (am-
picillin, gentamicin, and chloramphenicol) were added At the time of sacrifice (19 and 22 weeks), the kidneys
were removed. One kidney was fixed with buffered for-to the collection tubes. Urinary protein excretion was
determined by dipstick analysis (Roche, Indianapolis, malin, embedded in paraffin, then sectioned before stain-
ing with hematoxylin and eosin (H&E) or periodic acid-IN, USA).
Schiff (PAS) stain. The slides were read and interpreted
Measurement of anti-dsDNA Ab in a blinded fashion grading the kidneys for glomerular
inflammation, proliferation, crescent formation and ne-Anti-dsDNA antibody (Ab) levels were measured by
enzyme-linked immunosorbent assay (ELISA) as previ- crosis. Interstitial changes and vasculitis were also noted.
Scores from 0 to 3 were assigned for each of the featuresously described [18]. Briefly, 96-well ELISA plates were
coated with 5 g/mL double-stranded calf thymus DNA and then added together to yield a final renal score.
For example, glomerular inflammation was graded as(dsDNA) and incubated at 37C overnight. The plates
were then washed with phosphate-buffered saline (PBS) follows: 0  normal; 1  few inflammatory cells; 2 
moderate inflammation; and 3  severe inflammation.0.05% Tween (PBS-T). Sera were added in serial dilu-
tions, starting at 1/100 dilution to each well, and in-
Immunofluorescence stainingcubated for 45 minutes at room temperature (RT). After
washing with PBS-T, horseradish peroxidase (HRP) con- The other kidney was snap frozen and cut into 4-m
thick sections. The deposition of IgG and C3 were ana-jugated goat anti-mouse IgG (-chain specific; Sigma)
was added and incubated for 45 minutes. After additional lyzed in frozen sections by immunofluorescence after
incubating the slides with FITC conjugated rabbit antiwashing, a substrate solution containing 3,35,5-tetra-
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Fig. 2. Systolic blood pressure measurements in MRL/lpr mice given
L-NIL (1 mg/mL) or L-NMMA (50 mmol/L) in distilled drinking water.
Controls received distilled water alone. At 19 weeks mice were moni-Fig. 1. Urinary nitrate and nitrite (N/N) excretion by MRL/lpr mice
tored for systolic blood pressures by tail cuff measurement. Resultsgiven L-NIL (1 mg/mL; ) or L-NMMA (50 mmol/L; ) in distilled
shown are the mean  SEM of 10 mice.drinking water. Controls () received distilled water alone. Mice were
placed in metabolic cages weekly for 24-hour urine collection from 10
to 21 weeks of age. Results shown are the mean  SEM of 10 mice
from 10 to 18 weeks (2 mice per cage) and 5 mice after 18 weeks (1
mouse per cage). pressures by tail cuff measurement to determine the ef-
fects of L-NMMA and L-NIL on blood pressure. At
19 weeks of age, tail blood pressure measures in the
L-NMMA treated animals tended to be higher comparedmouse IgG (Sigma) and sheep anti mouse C3 (Sigma).
to the L-NIL and the control animals, although this in-IgG and C3 depositions were graded 0 to 3	 by a blinded
crease was not statistically significant (Fig. 2).observer.
To assess the role of NO inhibition on nephritis, we
Statistical analysis measured urine protein excretion by urine dipstick be-
The unpaired Student t test or analysis of variance ginning at 10 weeks of age (Fig. 3). From 10 to 14 weeks
(ANOVA) followed by post hoc analysis was used to of age, proteinuria remained low. After 14 weeks of age
test for significant differences between groups. A P value some mice in the control group began to develop protein-
of 
0.05 was considered significant. uria. The number of mice with proteinuria increased in
the control group over time. Some of the animals in the
L-NIL treatment group also began to have proteinuriaRESULTS
after sixteen weeks of age. However, the L-NMMATo determine if NO production was inhibited by treat-
treated animals did not develop proteinuria during thement with the two NOS inhibitors, we measured N/N in
treatment. By dipstick analysis, measurements at weekthe urine. In animals consuming a N/N-free diet, urinary
20 showed that 80% of the control mice had urine proteinexcretion of N/N accurately reflects the endogenous pro-
levels of 100 mg/dL or greater. In the L-NIL treatedduction of NO [13]. At 10 weeks of age, all mice had
mice, 40% showed urine protein of 100 mg/dL or greater.low urinary N/N excretion. In the control mice, NO pro-
The animals were assessed for differences in body,duction increased beginning at week 12 and remained
spleen and kidney weights at 19 and 22 weeks (5 perelevated for the duration of the study (Fig. 1). In contrast
group), as reduced kidney size is another indicator ofto the increase in urinary N/N excretion observed in the
medical renal disease. Neither body weights nor spleencontrols, mice that received either L-NMMA or L-NIL
weights were significantly different in any of the treat-had minimal increases in N/N excretion over the same
ment groups. However, the kidney and kidney-to-bodyperiod of time.
weight ratios in the L-NIL and the L-NMMA treatedL-NMMA treatment has known systemic effects in-
mice at 19 weeks were significantly greater than the con-cluding increasing blood pressure, in part, due to inhibi-
tion of endothelial NOS. We evaluated systolic blood trols (Fig. 4). Furthermore, at 22 weeks of age the L-NIL
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Fig. 4. Kidney weights relative to total body weights of MRL/lpr mice
receiving drinking water alone (controls, ); L-NIL (1 mg/mL; ) or
L-NMMA (50 mmol/L; ) in distilled drinking water. The results are
Fig. 3. Dipstick measurements of urine albumin from MRL/lpr mice shown as kidney weights (100) divided by total body weight at 19 and
given distilled water alone (control, ), L-NIL (1 mg/mL, ), or 22 weeks of age (N  5; *P 
 0.05).
L-NMMA (50 mmol/L, ) in the drinking water. Mice were placed in
metabolic cages for 24-hour urine collection once a week from 10 to
20 weeks of age. From 10 to 18 weeks, 2 mice were placed in each
metabolic cage (5 cages per group). After 18 weeks, 1 mouse was placed
To determine the effects of NO inhibition on glomeru-in each cage (5 mice per group). Each point represents the number of
cages that were determined to have proteinuria with scores of greater lar IC deposition, immunofluorescence analysis was pre-
than 100 mg/dL. formed. Frozen sections were stained with fluorescein-
conjugated and mouse IgG or C3 and scored by a blinded
observer on a scale from 0 to 3. When the scores were
averaged there was no qualitative or quantitative differ-treated mice continued to have kidney-to-body weight
ence between the control, L-NIL, and L-NMMA treatedratios that were significantly greater than the controls.
mice at 19 or 22 weeks of age (Fig. 6).At 19 and 22 weeks of age, five mice from each group
To investigate the possible mechanisms for modula-were sacrificed, kidneys removed and pathologic renal
tion of renal disease in L-NMMA and L-NIL treatedscores determined using a previously published scale for
mice, we measured levels of autoantibodies that are im-glomerular inflammation [18]. Figure 5 shows a repre-
plicated in disease pathogenesis. Anti-dsDNA Abs andsentative kidney section from a control, L-NMMA and
anti-GBM Abs are pathogenic in autoimmune nephritisL-NIL treated mouse at 22 weeks of age. The control
that develops in MRL/lpr mice. We measured anti-dsgroup showed significant pathologic renal findings in-
DNA Abs in the serum by ELISA (Table 2). As thecluding, diffuse glomerular hypercellularity, mesangial
mice aged, anti-ds DNA Abs increased in all groups withexpansion, crescent formation, fibrinoid necrosis, glo-
no significant difference between the groups except atmerular hyalinization, and infiltration of inflammatory
22 weeks, where there was a decrease in anti-dsDNAcells. Less renal disease was seen in the L-NMMA and
antibodies in the L-NMMA treated mice. There was nothe L-NIL treated mice as compared to controls. When
significant difference in antibody titers to GBM in thethe scores for disease activity were calculated, the mice
three groups (Table 2). Furthermore, serum total IgG,in the L-NMMA and L-NIL groups had pathologic indi-
IgG2a and IgG3 were similar in all three groups at allces that were significantly less than the controls at 19
time points (data not shown).weeks (Table 1). At 22 weeks, the L-NIL treated mice
At 22 weeks of age almost all MRL/lpr mice displaycontinued to have significantly reduced pathologic renal
external physical characteristics including excoriatingscores as compared to controls; however, the renal pa-
dermatitis and necrosis of ear lobes. Figure 7 shows con-thology scores in the L-NMMA treated mice were not
trol mice with a typical skin rash. All the mice treateddifferent from controls. Interstitial inflammation in the
with L-NMMA displayed skin lesions that were similarkidneys was similar in all three groups, as all lpr mice,
to those in the control mice, whereas none of the miceregardless of strain background, have interstitial in-
flammation. treated with L-NIL had signs of skin involvement.
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Fig. 5. Representative kidney section stained with H&E from a MRL/lpr mouse treated with L-NIL (1 mg/mL), or L-NMMA (50 mmol/L), or
distilled water only at 22 weeks of age in (A) control, (B) L-NMMA and (C ) L-NIL.
Fig. 7. Representative photographs of mice
at 22 weeks of age. (A) Control MRL/lpr mice
showing severe earlobe necrosis and skin der-
matitis. (B) MRL/lpr mouse treated with
L-NMMA (50 mmol/L) also showing earlobe
necrosis and skin dermatitis. (C) MRL/lpr
mouse treated with L-NIL (1 g/mL) showing
minimal signs of skin disease.
Table 1. Renal pathology of kidneys from MLR/lpr mice givenDISCUSSION
distilled water alone, L-NIL (1 mg/mL), or L-NMMA
(50 mmol/L) in the drinking waterGiven the conflicting results from our previous studies
on the effect of pharmacologic inhibition versus genetic Interstitial inflammation
deficiency of iNOS in MRL/lpr mice, we performed these
Renal score Focal Diffuse Vasculitis
studies to define further the role that iNOS plays in renal
19 weeksdisease in these mice. Two different agents that block Controls 8.22.7 1.80.3 1.60.5 3/5 mice
NOS activity were used: L-NMMA, a non-specific NOS L-NMMA 2.70.5a 2.60.5 2.40.4 4/5 mice
L-NIL 3.01.5a 2.60.5 1.50.7 2/5 miceinhibitor, and L-NIL, a specific inhibitor of the iNOS iso-
22 weeksform. Our results demonstrated that both L-NMMA Controls 10.21.7 2.00.0 1.60.5 3/5 mice
and L-NIL significantly decreased pathologic renal scores L-NMMA 9.51.7 2.80.3 2.20.6 4/5 mice
L-NIL 5.22.5a 2.00.0 0.750.3 2/5 micewhen compared to controls. L-NIL was of greater effi-
The kidney slides were interpreted in a blinded fashion and graded for glomer-cacy in long-term control of proliferative renal disease
ular inflammation, proliferation, crescent formation and necrosis. Data presented
than L-NMMA, but was less effective at blocking pro- are the mean  SEM of 5 mice in each group at 19 and 22 weeks of age (P 

0.05). The presence of interstitial inflammation is graded separately and vasculitisteinuria. As expected, neither L-NIL nor L-NMMA de-
is noted.
creased the serum levels of autoantibodies or affected
the glomerular deposition of IgG/C3-containing immune
complexes. These results indicate that specific pharmaco-
logic inhibition of iNOS is beneficial in preventing lupus- (eNOS) enzymes [19–25]. The constitutive isoforms of
like renal disease in MRL/lpr mice by inhibiting the NOS (nNOS and eNOS) are locally produced in the
inflammatory response induced by IC deposition. central and peripheral nervous system and in vascular
Three distinct isoforms of NOS are known, including endothelial cells and serve predominantly physiological
functions. In contrast, iNOS is synthesized de novo inneuronal (nNOS), inducible (iNOS) and endothelial
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Table 2. Serum anti-dsDNA and anti-GBM antibodies from
MRL/lpr mice at 12, 16, 19 and 22 weeks of age after treatment
with distilled water, L-NIL (1 mg/ml) or L-NMMA (50 mmol/L)
Control L-NMMA L-NIL
Serum anti-dsDNA
Ab levels
12 weeks 0.310.2 0.490.4 0.440.2
16 weeks 0.960.4 0.890.4 0.970.3
19 weeks 1.20.4 0.890.4 1.50.3
22 weeks 1.20.5 0.550.1a 1.00.4
Serum anti-GBM
Ab levels
12 weeks 0.60.2 0.700.3 0.60.2
16 weeks 1.20.3 1.00.4 1.10.2
19 weeks 1.80.3 1.20.5 1.30.3
22 weeks 1.40.2 1.20.3 1.30.3
Results shown are the mean  SEM of 10 mice from 10 to 19 weeks and 5
mice at 22 weeks (aP 
 0.05). Abbreviations are in the text.
times more specific for iNOS than for nNOS and over
30 times more specific for iNOS than for eNOS. At the
doses used in these studies, L-NIL was relatively specific
for iNOS as evidenced by the lack of effect of L-NIL on
blood pressure measures in the mice and the decreased
levels of N/N in the urine of the animals.
The mechanisms responsible for the increased levels
of NO in lupus mice are not completely known. Immune
complex deposition in the kidney appears to predate N/N
production and likely initiates the inflammatory cascade
through complement and/or Fc receptor activation [26–29].
In the MRL/lpr mouse, macrophages infiltrate the glo-
merulus and secrete pro-inflammatory mediators such
as IFN- and NO [6, 30, 31]. Mesangial cells also possess
the ability to secrete pro-inflammatory mediators in re-
sponse to inflammatory stimulation [32–35]. The relative
contribution of macrophages versus mesangial cells to
the production of inflammatory mediators and NO re-
mains unclear.
Several studies have demonstrated beneficial effects
of blocking NO production in glomerulonephritis [15,
36–38], whereas others have observed deleterious effects
of NO inhibition [39, 40]. In a rat model of induced glo-Fig. 6. Immunohistochemistry analysis of (A) IgG and (B) C3 deposi-
merulonephritis, anti-thymocyte serum (ATS) inducestion in the kidneys of MRL/lpr mice treated with L-NIL (1 mg/mL) or
L-NMMA (50 mmol/L) in distilled drinking water. Controls received glomerulonephritis and acute mesangial cell proliferative
distilled water alone. Fluorescence was graded on a scale from 0 to 3 glomerulonephritis. Studies by Narita et al showed thatby a blinded observer and is shown as the SEM of 5 mice in each
L-NMMA inhibited glomerulonephritis in rats givengroup at 19 ( ) and 22 ( ) weeks of age.
ATS and correlated these results with decreased mesan-
gial cell lysis, TGF- expression, and decreased extracel-
lular matrix accumulation [41]. Similar to our data withselected cell types after exposure to bacterial endotoxins
both L-NMMA and L-NIL, these experiments indicateor specific cytokines. The compounds used in these stud-
that pathologic renal disease can be treated distal toies, L-NMMA and L-NIL, show different selectivity for
immune complex deposition. In contrast to our currentthe three isoforms of NOS. The IC50 values for L-NMMA
studies showing a protective role with L-NIL treatment,are: iNOS 13.3 mol/L, eNOS 5.2 mol/L and nNOS 7.1
studies by McCartney-Francis et al demonstrated thatmol/L, making L-NMMA a non-specific NOS inhibitor.
selective iNOS inhibition with L-NIL exacerbated ero-The IC50 values for L-NIL are: iNOS 5.0 mol/L, eNOS
135 mol/L, and nNOS 54 mol/L. Thus, L-NIL is 10 sive joint disease [42]. In our previous studies using mes-
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angial cells, L-NIL addition did not lead to decreased represents the most successful class of therapeutic agents
for rheumatoid arthritis to date [51, 52]. Thus, the resultsiNOS protein expression [43], while in the studies by
McCartney-Francis et al L-NIL decreased iNOS protein of knockout studies do not necessarily mean that the
lack of effect of a knocked out gene on a disease processlevels in arthritic joint tissue, indicating that other mech-
anisms aside from the known enzyme inhibitor effects eliminates that gene as a good target for pharmacologic
intervention.of L-NIL may contribute to these disparate results.
Relatively specific iNOS inhibition was previously An alternative explanation for the contrasting results
of pharmacologic iNOS inhibition versus genetic abla-shown to have beneficial effects in another murine model
of lupus. Yang et al reported that administration of amino- tion of iNOS is that both L-NMMA and L-NIL have
additional effects on disease other than simply blockingguanidine reduced NO and TGF- production in NZB/
NZW mice [44]. Glomerular sclerosis, mean glomerular NO production. Both agents are arginine analogs and
block NO production by competing with arginine as acell number and urinary proteinuria also were decreased,
showing beneficial effects of relative iNOS inhibition. substrate for iNOS. Arginine is utilized by other biologic
Aminoguanidine, however, has other biologic effects in- systems that may impact renal disease (for example, bio-
dependent of inhibiting iNOS activity that may have logically active amines). It is possible, although we be-
played a role in the beneficial effects seen in these experi- lieve unlikely, that effects on these non-NOS pathways
ments. L-NIL is significantly more specific for iNOS than influence disease progression. Derivation of inhibitors of
aminoguanidine, allowing a clearer assessment of the ef- iNOS that are not arginine analogs would allow delinea-
fects of specific inhibition of iNOS on lupus-like glomer- tion of this possibility.
ulonephritis. In summary, these studies demonstrate that iNOS de-
A specific iNOS inhibitor would be preferred as a rived NO plays a key role in the development of prolifer-
pharmacologic agent in humans due to the potential tox- ative glomerulonephritis in MRL/lpr mice. Inhibition of
icity of non-specific NOS inhibitors [45, 46]. Although all three isoforms of NOS leads to diminished proteinuria
not clinically proven, elevation in blood pressure, pos- and lower renal pathology scores compared to untreated
sible central nervous system (CNS) dysfunction and im- controls. Furthermore, treatment of MRL/lpr mice with
potence are predicted side effects of non-specific NOS a specific iNOS inhibitor results in long-term sustained
inhibition [47]. Constitutively produced NO lowers glo- significant improvement in renal scores and decreased
merular pressure and thereby protects against pressure- skin disease as compared to controls. These studies sug-
induced renal injury. This effect on intra-glomerular gest that specific iNOS inhibitors may have therapeutic
pressure may account for the significant improvement value in the treatment of lupus nephritis.
in renal score at 22 weeks we observed in the L-NIL
treated mice compared to the L-NMMA treated mice. ACKNOWLEDGMENTS
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